TEL AVIV, Israel and RALEIGH, N.C., Dec. 11, 2018 /PRNewswire/ — MaxQ AI, a clinical diagnostics intelligence platform company, today announced a distribution agreement with the EnvoyAI subsidiary of TeraRecon. TeraRecon is a leader in advanced visualization and artificial intelligence solutions. As part of this agreement, MaxQ’s innovative Accipio™ intracranial hemorrhage (ICH) platform, components of which have received FDA Breakthrough status and whose Accipio Ix™ ICH identification and triaging solution recently received FDA clearance, will now be a premier clinical solution available through the EnvoyAI Exchange marketplace. Accipio Ix will be sold through EnvoyAI and TeraRecon’s comprehensive PACS distribution channels and to the TeraRecon installed base of customers. The Accipio platform, working in combination with TeraRecon’s Northstar AI Results Explorer™, offers powerful first-of-kind physician workflows for ICH that are unmatched in radiology today.

“Our agreement with EnvoyAI will enable hospitals around the world to have access to our revolutionary AI-enabled Accipio platform for approved commercial use in their emergency rooms and for clinical research purposes,” said Chris Schnee, SVP Commercial Operations for MaxQ AI. “This partnership further accelerates the adoption of MaxQ solutions by acute care hospitals, which are TeraRecon’s core customer base. We are proud to be collaborating commercially with a market share leader in radiology advanced visualization. With Accipio Ix™ having both FDA clearance and CE Mark certification, U.S. and E.U. patients are soon to receive the benefit of augmented intelligence; the combination of the MaxQ AI empowerment coupled with the skills of the caregiver. Better together.”  

“We believe strongly in this concept of augmented intelligence, whereby the physician remains in control, interpretations are better informed and workflow is accelerated simultaneously,” said Jeff Sorenson, President and CEO of TeraRecon. “Our Northstar AI Results Explorer™ plays a pivotal role in allowing physicians to consume Accipio Ix results in many different ways, while always respecting the physician’s preferences and belief system. This is especially useful for inclusion of the innovative, but investigational-use only results, from Accipio Ax™ and Accipio Dx™. Physicians control what results are viewed and when, where they appear in the PACS workflow, and what images and findings persist in the PACS archive. MaxQ has done an outstanding job of utilizing the EnvoyAI platform and TeraRecon’s Northstar* technology to the fullest.”

MaxQ’s Accipio platform is designed to be highly sensitive to the presence of ICH – commonly known as a brain bleed – identifying and prioritizing patients with ICH for the treating physician. Accipio Ix is the first part of the ecosystem and has received both FDA clearance and CE Mark certification. It provides a capability for rapid escalation and prioritization of a brain bleed due to stroke or head trauma and can be natively integrated into CT and PACS systems using the imaging industry-standard DICOM, installed both on-premise and in the future, cloud-capable.

About MaxQ AI, Ltd.
MaxQ AI is at the forefront of transforming healthcare by empowering physicians to provide ‘smarter care’ with artificial intelligence (AI) clinical insights. Based in Tel Aviv, Israel and Andover, MA, our team of deep learning and machine vision experts develop clinical diagnostic intelligent software solutions that enable timely and more accurate diagnosis. Working with world-class clinical and industry partners, we are raising the level of acute care in hospitals around the world to improve patient outcomes and lower costs. To learn more, please visit www.maxq.ai or follow us on Twitter and LinkedIn.

About EnvoyAI
EnvoyAI is committed to delivering premium artificial intelligence innovations to empower the physician workflow. By intersecting sophisticated solutions with simple implementation, EnvoyAI is enabling the broad exploration and pragmatic application of artificial intelligence in healthcare. EnvoyAI is a wholly-owned subsidiary of TeraRecon poised for growth and investment. For further information, email info@envoyai.com or visit www.envoyai.com.

About TeraRecon
TeraRecon is a leader in advanced visualization, image viewing, and post-processing. Our flagship product, iNtuition, consistently leads the advanced visualization category of the industry’s leading independent technology analyst. We are committed to redefining advanced visualization by leveraging artificial intelligence, and to improving radiology workflow through personalized automation features that increase efficiency. For further information, email info@terarecon.com or visit www.terarecon.com.

*Northstar is currently in development. Not available for diagnostic use. 

View original content to download multimedia:http://www.prnewswire.com/news-releases/maxq-ai-partners-with-envoyai-to-distribute-accipio-artificial-intelligence-solutions-to-us-and-eu-acute-care-300763082.html

SOURCE MaxQ AI, Ltd.